SMF编写及内容要求注释-EN+CN.docx
《SMF编写及内容要求注释-EN+CN.docx》由会员分享,可在线阅读,更多相关《SMF编写及内容要求注释-EN+CN.docx(32页珍藏版)》请在淘文阁 - 分享文档赚钱的网站上搜索。
1、EudraLexThe Rules Governing Medicinal Products in the European Union欧盟药事法规Volume 4第4卷Brussels, 10 December 20092009年12月10日,布鲁塞尔EU Guidelines to欧盟指南Good Manufacturing Practice Medicinal Products for Human and Veterinary Use人用药品及兽药生产质量管理规范Part III第III部分Explanatory notes for pharmaceutical manufacturer
2、s on the preparation of a Site Master File and content of a Site Master File药品制造企业现场管理档案(SMF)内容及编写要求注释翻译:徐禾丰2009年12月,第1版Draft agreed by GMP/GDPInspectors Working GroupsGMPGDP检查员工作组批准草案September 20092009年9月Release for public consultation发放征求意见15 December 20092009年12月15日Deadline for comments entr-gmpe
3、c.europa.eu and ADMGMDPema.europa.eu提交意见给 entr-gmpec.europa.eu与ADMGMDPema.europa.eu的最后期限31 March 20102010年3月31日Final text agreed by GMP/GDP Inspectors Working GroupsGMPGDP检查员工作组批准最后文本Adopted by European Commission欧盟委员会批准Deadline for coming into operation实施运行最后期限The Site Master File concept has been
4、developed by PIC/S and has become a standard expectation of EU authorities. Following a recent revision of the explanatory notes by PIC/S, it has been proposed that the status of the Site Master File is more formally linked to the EU regulatory framework.现场管理档案的概念由PICS开发,并已经成为欧盟当局的一个标准的期望。继最近PICS修订解
5、释性说明,已经建议SMF地位更加正式地连接到欧盟药政法规架构中。It is proposed that a new informational Part III of the EU GMP Guide is created for documents which are not themselves GMP guidelines and have no statutory force but which complement the GMP guidelines and related regulatory procedures such as, in this case, inspectio
6、ns.建议欧盟GMP指南第III部分编制为新的信息文件,但其本身不是一个GMP指南,也不具有法定效力,但作为GMP指南的一个补充和相关的药政程序,例如,检查。It is expected that in the future, further documents will be added to the new Part III and that such documents would be included following public consultation.希望在未来将有更多的文件添加到新的第III部中,并且这些文件也将包括在发放征求意见中。The document is ide
7、ntical to the content of the Site Master File by PIC/S and is published in parallel.该文件与PICS的现场管理档案内容一致,并平行发布。Table of contents目录1.INTRODUCTION.2.PURPOSE.12目的3.SCOPE.23范围24.CONTENT OF A SITE MASTER FILE.24现场管理档案内容Annex附件EU-GMP Part III(20091215) Site Master File欧盟GMP第III部分(20091215)现场管理档案1.INTRODUCT
8、ION1简介1.1The Site Master File is prepared by the pharmaceutical manufacturer and should contain specific information about the quality management policies and activities of the company, the production and/or quality control of pharmaceutical manufacturing operations carried out at the named site and
9、 any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, a Site Master File need only describe those operations,e.g.analysis,packaging,etc.现场管理档案由制造企业编写,包括关于质量管理方针与公司活动、指定现场进行药品制造运行、和或质量控制、以及在相邻或附近的建筑里进行的任何相关操作的具体信息。如
10、果现场只进行药品生产的部分活动,现场管理档案只需描述这些操作,例如,分析、包装等。1.2When submitted to a regulatory authority, the Site Master File should provide clear information on the manufacturers GMP related activities that can be useful in general supervision and in the efficient planning and undertaking of GMP inspections. 当提交给药政机构
11、时,现场管理档案应当提供制造商GMP相关活动的清晰资料,这些资料在一般监管、有效地规划以及采取GMP检查中十分有用。1.3A Site Master File should be detailed enough but, as far as possible, not exceed approximately twenty-five to thirty A4 pages plus appendixes.现场管理档案应当足够详细,加上附录,用A4纸,应不超过大约25到30页。1.4The Site Master File should be a part of documentation bel
12、onging to the quality management system of the manufacturer and kept updated accordingly. The Site Master File should have an edition number and effective and expiry dates. It should be subject to regular review to ensure that it is up to date and representative of current activities. The format and
13、 headings should follow these guidance notes.现场管理档案应当属于制造企业质量管理体系文件的一部分,并相应地保持最新。现场管理档案应当有版本编号以及有效期。其应当定期进行审核,以确保它是最新,并代表当前的活动。格式和标题应该遵守这些指南的注释。1.5Wherever possible,simple plans, outline drawings or schematic layouts should be used instead of narrative. These plans etc should fit on A4 sheets of pap
14、er and copies should be readable.如果可能,用简单的平面图,略图或者图解代替文字叙述。这些平面图等应该印在A4纸上,印制应当清晰。2.PURPOSE2目的The aim of these Explanatory Notes is to guide the manufacturer of medicinal products in the preparation of a Site Master File that can be useful to the regulatory authority in planning and conducting GMP in
15、spections.本注释的目的是为了指导药品制造企业编写现场管理档案,该档案有利于管理当局策划和执行GMP检查。翻译:徐禾丰2009年12月,第1版第1页下载高清无水印EU-GMP Part III(20091215) Site Master File欧盟GMP第III部分(20091215)现场管理档案3.SCOPE3范围These Explanatory Notes apply to the preparation and content of the Site Master File. Refer to national regulatory requirements to estab
16、lish whether it is mandatory for manufacturers of medicinal products to prepare a Site Master File and supply it and version updates to the Supervisory Authority.本注释适用于现场管理档案的编写及其内容要求。请参阅国家法规要求,以确定是否强制药品制造企业制作现场管理档案,并向监管当局提交与更新版本。These Explanatory Notes apply for all kind of manufacturing operations
17、 such as production, packaging and labelling, testing, relabelling and repackaging of all types of medicinal products as well as active pharmaceutical ingredients. This guide could also be used in the preparation of a Site Master File or corresponding document by Blood and Tissue Establishments.这些注释
18、应用于所有类型的制造操作,例如,所有类型的产品以及原料药的生产、包装与贴签、测试、再贴签及再包装。本指南还可用于血液与组织机构的现场管理档案或相应文件的编制。4.CONTENT OF A SITE MASTER FILE4现场管理档案内容Refer to Annex for the format to be used.所采用格式参见附件。翻译:徐禾丰2009年12月,第1版第2页EU-GMP Part III(20091215) Site Master File欧盟GMP第III部分(20091215)现场管理档案Annex附件CONTENT OF A SITE MASTER FILE现场管理
19、档案内容1.GENERAL INFORMATION ON THE COMPANY公司一般信息1.1Contact information on the firm 公司联络信息Name and official address of the company;公司名称与官方地址;Names and street addresses of the site,buildings and production units; 现场、建筑与生产部门名称与街道地址;Contact information of the company including 24 hrs telephone number of t
20、he contact personnel in the case of product defects or recalls;.公司联络信息,包括在产品缺陷或召回时24小时联系人电话号码;Identification number of the site such as e.g. DUNS, if available; 如果有,该现场识别号码,例如,邓白氏公司号码;GPS details.GPS详细情况。1.2Pharmaceutical manufacturing activities as licensed by the Competent Authorities. 官方许可的药品制造活动
21、Brief description of manufacture, import, export, distribution and other activities as authorized by the relevant Competent Authorities including foreign authorities with authorized dosage forms/activities,respectively;简要描述相关官方所许可的制造、进口、出口、分销与其它活动,也包括国外官方许可的剂型活动;Copy of the valid manufacturing autho
22、risation issued by the relevant Competent Authority and, if available, also for API manufacturers in Appendix 1;or when applicable, reference to EudraGMP.相关官方签发的有效制造授权书副本,如果有,也适用于附录1的原料药制造企业;适用时,可参考EudraGMP。翻译:徐禾丰2009年12月,第1版第3页下载高清无水印EU-GMP Part III(20091215) Site Master File欧盟GMP第III部分(20091215)现场
23、管理档案Type of products currently manufactured on-site (list in Appendix 2); 当时现场所制造产品的类型(列于附件2);General information if toxic or hazardous(i.e. with high pharmacological activity and/or with sensitising properties) substances are handled on the site;现场所处理的有毒或有害(例如,高药理活性,和或,敏感性质)物质一般信息;Key parameters (e
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- SMF 编写 内容 要求 注释 EN CN
限制150内